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Abstract
Background: It is known that alpha-defensin expression is enhanced in colon cancer. However, the expression of
human alpha defensin 6 (DEFA 6) in earlier stages, such as adenoma, has so far not yet been studied in a patient
resolved manner.
Methods: By using quantitative Real Time-PCR, the gene expression pattern of DEFA 1-3 and DEFA 6 was analyzed
in tissue of different stages of carcinogenesis, derived from colorectal cancer patients. In addition to paired normal
and tumor tissue, matched normal near tumor and adenoma tissue samples were examined.
Results: The median gene expression of human defensin alpha 6 (DEFA 6) has been found to be moderately
increased (~5 fold) in tumor samples derived from individuals with colorectal cancer (CRC) when compared to
their normal counterparts. However, when the data were analyzed in a patient-wise manner, a large expression
variation among individual patients is found, making the use of DEFA 6 for individual diagnosis of fully blown
colon carcinoma difficult. Surprisingly, in adenoma the gene expression analysis revealed a 100 fold increased
median expression of DEFA 6 relative to normal colon tissue. 13/18 samples had an individual overexpression of
more than 60 fold in adenoma but only 3/17 in carcinoma. In each of the individual patients, at least either the
adenoma or the carcinoma showed strong DEFA 6 overexpression.
Conclusions: We suggest that the expression of DEFA 6 preferably can be used as a potential diagnostic marker for
adenoma and not as a marker for fully blown carcinoma. This is supported by the fact that DEFA 6 is a downstream
target of the Wnt pathway, which is mutational active during the earliest stage of cancer development.
Background
Human neutrophilic (DEFA 1-3) and enteric (DEFA 6)
alpha defensins are cationic short peptides of 29 to 42
amino acids in length with known functional activities in
innate antimicrobial immunity [1-3]. While DEFA 1-3 are
major components of the dense azurophilic granules
of neutrophils, DEFA 6 is primarily expressed in the
lysozyme-rich granules of the Paneth cells of the small
intestine [4], but also found in intermediate cells [5]. As
involved in the host defense of the gut, the expression of
alpha defensins is usually found to be elevated in chroni-
cally inflamed colon, but not in the respective healthy tis-
sues [5,6]. Furthermore, several studies already reported
the elevated alpha defensin expression in various tumour
types, suggesting their potential to be used as tumour mar-
kers [6-9]. Their expression was shown to be enhanced in
fully blown colon cancer tissue, though an evaluation of
individual patient’s data has not yet been reported [10-12].
More interestingly, in contrast to DEFA 1-3, which has
been shown to be an unspecific colon cancer marker,
DEFA 6 is more tissue specific due to its high expression
in colon cancer as compared to other tumors [11].
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any medium, provided the original work is properly cited.This study attempts to test whether DEFA 6 can be
used as marker of the adenoma stage of colon cancer
and not solely, as already described in literature, as a
marker of fully blown colorectal cancer. The emphasis is
on evaluating the data on an individual patient’sb a s i s
before pooling the data, since a high median overexpres-
sion, at large variation of the individual patient’s data,
would not be really suited for a diagnosis.
Methods
Tissue sample preparation for gene expression analysis
Tissue samples were prepared as described in Radeva
et al [13]. In short, the normal colon samples from each
patient with colon cancer were taken at a distance of 20
to 50 cm from the tumor site. Confirmation of the
tumor stage of the patients was provided by pathological
examination after the surgery (Table 1). In addition to
the adenoma, macroscopically normal tissues, removed
at distance 1 to 5 mm apart from the tumor were col-
lected. All of the obtained adenoma samples were
benign. Only hyperplastic polyps and villous or tubular
adenomas were taken, but not flat serratous adenomas
since these might have different pathology.
Ethics
The research was carried out in compliance with the Hel-
sinki Declaration. Furthermore, the study was institution-
ally approved by the ethics committee of University
Hospital of Jena, Germany (Reference number 1601-08/
05). Prior to tissue collection, verbal consent was
obtained from all analysed patients.
Total RNA extraction from tissue samples. cDNA
preparation
Total cellular RNA preparation was performed as
described in Radeva et al [13]. In short, RNA was iso-
lated from epithelium colon stripes using RNeasy Mini
Kit (Qiagen, Hilden, Germany). Integrity of the isolated
total RNA was checked by using an Agilent 2100 bioa-
nalyzer (Agilent Technologies, Palo Alto, CA, USA).
cDNA synthesis was performed as described earlier [13].
However, due to the variability of the quantity of the
extracted total RNA, the amount used as an initial
material for the performance of the cDNA synthesis var-
ied (ranged from 10 ng to 300 ng total RNA).
Design of primers
All primer pairs were designed using freely available Pri-
mer3 software, version 0.4.0 http://frodo.wi.mit.edu/. To
assess the primer specificity, basic local aligment search
tools (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi)
were applied. The amplicon size varied within the range
from 160 bp to 222 bp. Sequences of the used primer
pairs are shown in Table 2. Besides the lack of DEFA 2
gene, the sequence of the genes encoding DEFA 1 and
DEFA 3 differ by only 2 nucleotide substitutions [14],
therefore one primer pair was used for detection of all
neutrophilic defensins. For further verification of the
primer specificity, the products amplified by defensin’s
primer pairs were sequenced.
Verification of the primer’s specificity
To verify the primer specificity and to ensure that the
designed primer pairs were not amplifying additional
p r o d u c t si nt h ep r e s e n c eo fg e n o m i cD N A ,in-silico
PCR, http://genome.ucsc.edu/cgi-bin/hgPcr?command=-
start was implemented. In addition to this computa-
tional procedure, experimental approach such as
standard polymerase chain reaction (PCR) was carried
out. For generation of the amplicon, reflecting the rela-
tive abundance of certain target gene, the gene specific
primers were tested in a presence of various templates,
such as genomic DNA (gDNA) and complementary
DNA (cDNA). Non-template control reaction (NTC)
that contains all essential components of the amplifica-
tion reaction except the template enables detection of
contaminations.
Amplification was performed using Go Tag DNA
Polymerase (Promega) with the following thermal condi-
tions: 95°C for 2 min followed by 40 cycles of 95°C for
30 sec, 60°C for 30 sec and 72°C for 30 sec and as a last
step, final extension at 72°C for 10 min was run. On
Figure 1, representative examples are shown. If the pri-
mers are specific, amplicon with correct size should be
observed only in case where cDNA was used as a DNA
template.
PCR reaction efficiency
Validation of the PCR reaction efficiency and the perfor-
mance of the quantitative RT-PCR assay was done as
previously described [13]. Two microliters cDNA
Table 1 Clinicopathological characteristics of 17 patients
Patient and tumor
characteristics
Number of cases
Age Mean age 68.7 ± 9.3
Gender 13 males, 4 females
Type of analyzed tissue*
Normal 17
Normal near Tumor 9
Adenoma 18**
Tumor 17*** (1 with G1, 6 with G2; 8 with G3; 1
with G4)
*Four different types of tissues were examined for expression of DEFA 1-3,
DEFA 6 and b- actin genes.
**One donor has two types of adenoma.
***For 1 out of 17 analyzed donors the clinical description about the grade of
the tumor was not available. In addition, 1 out of the total 17 donors
investigated does not possess tumor tissue.
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RNA was used as a template. Prior further evaluation,
the data was additionally normalized to definite starting
concentration in order to remove the errors introduces
due to uneven sample quantities. The normalization
algorithm is available from the authors upon request.
Statistical analysis
All samples were amplified in duplicate or triplicate and
the means were obtained for further calculations. In all
samples analyzed, the mRNA of each target gene was
normalized to that of the b-actin mRNA. The relative
RNA expression was calculated using the following
formula:
2
() Ct reference-Ct gene of interest
where Ct corresponds to the number of cycles needed
to generate a fluorescent signal above a predefined
threshold. The averaged Ct value for the reference gene
was subtracted from the averaged Ct value of the
selected gene of interest.
The data was exported to GraphPad Prism Software,
version 4 (Graph Pad, San Diego, USA). Comparisons
between two groups were made using Wilcoxon matched
pairs test. Overall differences between multiple groups
were tested using the nonparametric Kruskal-Wallis test.
Results
Gene expression profiling of human subjects
In the present work, the expression of DEFA 6 gene was
tested and compared with the respective expression of
DEFA 1-3 genes. For this purpose, tissue samples of 17
CRC patients were studied. Since the gene expression
analysis of fully blown carcinoma does not account for
the expression alterations that are critical for the initia-
tion and the development of cancer, in addition to the
classical combination of paired normal and tumor tissue,
also matched normal near tumor and adenoma tissue
samples were examined by qRT-PCR.
Low abundance of DEFA 1-3 expression in colon tissues
The expression of DEFA 1-3 genes was investigated in
normal and the related normal near tumor, benign ade-
noma and tumor tissue samples derived from 17 patients
in total. Resume of the performed quantitative Real
Time-PCR is presented in Figure 2.
Transcription levels of DEFA 1-3 mRNA, in all colon tis-
sues investigated were relatively low, when compared to
the expression of DEFA 6 (see below). Although low
Table 2 Sequence of oligonucleotide primers used for PCR amplification and product size predicted for sample cDNA
Gene name Gene annotation RefSeq ID Sequence Amplicon size
DEFA 1-3* Defensin, alpha 1 to 3 NM_005218.3 CCTGCCTAGCTAGAGGATCTGTG 222 bp
NM_005217.2 TGTTTTTCCTTGAGCCTGGA
DEFA 6* Defensin, alpha 6, Paneth cell-specific NM_001926.2 CTCAAGTCTTAGAGCTTTGGGCT 198 bp
GGACACACGACAGTTTCCTTC
b-actin* Beta actin NM_001101 AGAGCCTCGCCTTTGCCGAT 160 bp
CCCACGATGGAGGGGAAGAC
*All primers are listed as 5’ to 3’.
Figure 1 Verification of primer specificity. (A) Defensin alpha 6 (DEFA 6) and (B) Defensin alpha 1-3 (DEFA 1-3). The expected amplicon size is
198 bp and 222 bp, respectively. In order to verify the lack of contaminations, non-template control reaction (NTC) was run in parallel.
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in adenoma and tumor tissues compared to the normal
samples with ~4- and 6.4-fold, respectively (Wilcoxon test,
p = 0.0007 (adenoma vs. normal), p = 0.02 (tumor vs. nor-
mal)). Moreover, the expression in normal near tumor was
also increased by factor of 2.8 over normal tissue (Wil-
coxon test, p = 0.04). The expression alterations among
normal near tumor, adenoma and tumor colon tissues
were relatively small, in the range of 1.33 to 1.4 fold, and
according to the performed Wilcoxon matched pairs
test all of these differences were not statistically significant
(p > 0.5).
In summary, the presented results verified the general
observation of DEFA 1-3 elevation in colon tumors,
which consist of a mix of different cell populations such
as epithelial cells, a small percentage of fibroblasts and
leukocytes. Therefore, it is still unclear whether the
invasion of the neutrophils or the defensin production
by the cancer cells themselves is the reason for the
altered DEFA 1-3 expression in colon cancer tissues
samples [6,8,15,16].
A burst of DEFA 6 in benign adenoma
As for DEFA 1-3, the expression of DEFA 6 gene was
investigated across the adenoma-carcinoma axis. The
outcome of the analysis is summarized in Figure 3.
The increase in DEFA 6 expression when compared to
the rest of the tested groups is immediately evident. The
horizontal lines represent the median expression of the
population analyzed indicating significant increase with
a 100 fold in adenoma over normal tissue (Wilcoxon
test, p = 0.0004). Still large was the increase of DEFA 6
in adenoma over the normal near tumor tissue (30.6
fold), and this expression’s alteration, according to the
applied Wilcoxon test, was significant (p = 0.02). When
t h em e d i a ne x p r e s s i o ni nt u m o rw a sc o m p a r e dw i t h
that in normal tissues, moderate increase with almost 5
f o l dw a sd e t e c t e di nf u l l yb l o w nt u m o r st h a ni nt h e
non-malignant, normal samples, and those differences,
based on the performed statistical test, were significant
(p = 0.012).
A 100 fold average increase in one single stage of
colon cancer development is a comparably strong
genetic marker. However, the full potential of these data
becomes only evident when it is presented in a patient
specific manner. Thus, Figure 4 summarizes the com-
puted DEFA 6 expression ratio between adenoma and
normal (rhombs) as well as between tumor and normal
(squares) colon tissue, obtained from each single indivi-
dual analyzed. The patient’sc h a r a c t e r i s t i cs u c ha sa g e ,
gender and grade are denoted below the figure. No con-
sistent dependence of DEFA 6 expression ratios as a
function of tumor grade, age or gender has been
detected. The ratios in adenoma as well as in carcinoma
as compared to normal tissue vary more than 1000 fold
indicating the individuality of each patient’s cancer.
However, DEFA 6 is overexpressed in all cases either in
adenoma or carcinoma - which indeed means that all
Figure 2 Gene expression of DEFA 1-3.T h eDEFA 1-3 expression
was normalized to b-actin, in normal, normal near tumor, adenoma
and the respective tumor tissue samples. For better visualization the
scale was segmented with suppression of the highest values. The
horizontal lines represent the median over all investigated patients.
Differences between multiple groups were tested using Kruskal-
Wallis test. Significant up-regulation was observed in adenoma
tissue over the related normal colon tissue (*p < 0.05). The rest of
the comparisons did not show significance according to the test
(p > 0.05).
Figure 3 Relative gene expression of DEFA 6 as already
described for Figure 2. According to the performed Kruskal-Wallis
test, the median expression in adenoma as compared to normal
tissue was significantly elevated (p< 0.001).
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normal. In addition, in 13/18 cases (72%) an overexpres-
sion of more than 60 fold indicates an adenoma (see
Figure 4, the black horizontal line is empirical and sepa-
rates all samples with overexpression of 60 or more fold
from the rest of the samples). Most of the tumor tissues
showed overexpression with less than 60 fold. In addi-
tion, we did not find a correlation between the DEFA 6
expression in adenoma and carcinoma which might be
systematically related to the grade of the tumor.
Discussion
Enhanced alpha-defensin gene expression can be
detected in samples such as stool [16], serum, plasma
[6,10] and colon tissue [11,12,15] derived from colorectal
cancer patients. In this sense, our results on the DEFA 6
gene in colon cancer tissues is in agreement with Nam
et al. There by ELISA, DEFA 6 was also found to be
enhanced on the protein expression level in serum from
colorectal cancer patients indicating a good correlation
between DEFA 6 mRNA and protein expression. DEFA 6
showed even a higher diagnostic sensitivity and specifi-
city than CEA, the most widely used marker for colon
cancer diagnosis [11]. Thus, the observed stable correla-
tion between DEFA 6 mRNA and protein expression
indicates that no dramatic posttranscriptional regulation
occurs. It would also be interesting to address the ques-
tion what are the serum DEFA 6 expression levels of
patients with adenoma only. However, such patients are
difficult to be obtained due to the fact that in most of the
cases the patient is diagnosed too late, when the carci-
noma has been already fully developed.
In adenoma, we detected extremely high DEFA 6
expression in almost all individual patients. This makes
DEFA 6 a suitable target for diagnosis of individuals. In
12 out of 17 samples the effect of DEFA 6 overexpres-
sion in adenoma was reverted in the fully blown tumor.
Thus, DEFA 6 expression in tumor was distinctly lower
compared to adenoma, but still remained higher than in
normal tissue.
To our best knowledge this is the first study demon-
strating a gene expression explosion of DEFA 6 in prema-
lignant adenoma obtained from patients with colorectal
cancer. This striking result suggest that the high DEFA 6
overexpression is the hallmark of adenoma, since the
expression threshold of 60 fold (see Figure 4) discrimi-
nates adenoma from carcinoma in a sharper way than
many other disease markers for individual patients and
may thus be envisioned as a simple auxiliary diagnostic
tool for the clinical histologist.
Neoplastic tissue is well known to be heterogeneous.
Thus, a large proportion of adenoma and carcinoma
Figure 4 Up or down - regulation of DEFA 6 expression in 17 individuals*. *One of the donors had two adenomas, therefore the figure
show 18 samples. The patients are characterized for their age, gender and grade of cancer. N.D. means that the stage was not determined. The
scale of the y axis is logarithmic. None of the patients has simultaneously down-regulated DEFA 6 in both, adenoma as well as fully blown
cancer. The dotted horizontal line at 1 indicates that DEFA 6 expression would be un-effected. For the first patient on the left, no comparison of
adenoma with carcinoma was possible, since the donor had developed only adenoma. From the 17 other samples, 13 revealed a higher
expression in adenoma than in carcinoma, 1 case (encircled) showed essentially no change and 3 objects (in rectangular boxes) had the highest
expression in carcinoma.
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under investigation. As an example, Ki-67 and Myc,
known markers for proliferation, were found to be over-
expressed in areas of increased cell proliferation [17,18].
On other hand, Andreu et. al reported that the DEFA 6
mRNA expression level was elevated in tumors, where
Myc and Cyclin D were accumulated as well [19]. This
is not surprising due to the fact that the three genes are
known to be down stream targets of the same pathway,
namely Wnt pathway. Therefore, if within the tumor the
mRNA expression of DEFA 6 is in stable positive cor-
relation with the mRNA expression of well known
proliferation markers, such as Myc, strong DEFA 6
expression can be seen in areas of the tumor associated
with a higher proliferation.
Conclusions
To our knowledge this is the first study demonstrating a
strong burst of the DEFA 6 gene in human adenoma tis-
sue samples. This observation immediately indicates the
potential of DEFA 6 to be used as a marker for early
premalignant stages of colorectal cancer and not solely
as a marker for colon cancer detection.
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